Photo by nci from unsplash
Statins reduce risk of major adverse cardiovascular events (MACE) in women and men; whether the same holds true for PCSK9 inhibition is uncertain. The ODYSSEY OUTCOMES trial compared alirocumab with… Click to show full abstract
Statins reduce risk of major adverse cardiovascular events (MACE) in women and men; whether the same holds true for PCSK9 inhibition is uncertain. The ODYSSEY OUTCOMES trial compared alirocumab with placebo, added to high-intensity or maximum-tolerated statin treatment, in 4,762 women and 14,162 men
Keywords:
cardiovascular outcomes;
outcomes trial;
alirocumab cardiovascular;
odyssey outcomes;
outcomes women
Journal Title: Journal of the American College of Cardiology
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of the American College of Cardiology
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!